BAY1831865 / Aronora, Xoma, Bayer - LARVOL DELTA

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men. (PubMed, J Thromb Haemost) - "BAY 1831865 i.v. or s.c. was well tolerated, with no evidence of bleeding in healthy volunteers. BAY 1831865 exhibited pronounced, sustained dose-dependent prolongation of aPPT and duration of FXI inhibition."

Journal • PK/PD data • Hematological Disorders • Immunology